Shopping Cart 0
Cart Subtotal
USD 0

Infinity Pharmaceuticals Inc (INFI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Infinity Pharmaceuticals Inc (Infinity Pharmaceuticals) is a biopharmaceutical company that discovers and develops small molecule therapeutics for the treatment of cancer. The company's pipeline candidate: IPI-549 selectively inhibits PI3K-gamma to reprogram tumor-associated macrophages and transforms immuno-oncology approach. It is evaluating IPI-549 as a monotherapy in Phase 2 for a solid tumor. Infinity Pharmaceuticals is also investigating IPI-549 in Phase 1 for solid tumors, and in Phase 1B for non-small cell lung cancer (NSCLC), melanoma, squamous cell carcinoma of the head and neck (SCCHN), triple negative breast cancer (TNBC), mesothelioma, adrenocortical carcinoma, and myeloid-derived suppressor cells (MDSC). Infinity Pharmaceuticals is headquartered in Cambridge, Massachusetts, the US.

Infinity Pharmaceuticals Inc (INFI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 11

Partnerships 12

Bristol-Myers Squibb and Infinity Pharma Enter into Collaboration Agreement 12

Arcus Biosciences and Infinity Pharma Enter into Clinical Collaboration Agreement 13

Bristol-Myers Squibb Expands Agreement with Infinity Pharma 14

Pharm-Olam International Enters into Agreement with Infinity Pharma 15

Lead Discovery Center Partners with Infinity Pharma 16

Licensing Agreements 17

PellePharm Enters into Licensing Agreement with Infinity Pharma 17

Verastem Enters into Licensing Agreement with Infinity Pharma for Duvelisib 18

FAAH Pharma Enters into Licensing Agreement with Infinity Pharma 20

Equity Offering 21

Infinity Pharma Plans to Raise USD2.5 Million in Public Offering of Shares 21

Infinity Pharmaceuticals to Raise USD50 Million in Offering of Common Stock 23

Infinity Pharma Completes Public Offering Of Common Stock For USD 173 Million 24

Infinity Pharma Completes Private Placement Of Shares For USD 78.5 Million 26

Infinity Pharma Completes Public Offering Of Common Stock For USD 88 Million 27

Infinity Pharmaceuticals Inc-Key Competitors 29

Infinity Pharmaceuticals Inc-Key Employees 30

Infinity Pharmaceuticals Inc-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Recent Developments 32

Strategy And Business Planning 32

Nov 07, 2018: Bristol-Myers and Infinity partner for trial of opdivo and IPI-549 32

Financial Announcements 33

Nov 05, 2018: Infinity Pharmaceuticals provides company update and third quarter 2018 financial results 33

Aug 07, 2018: Infinity Pharmaceuticals provides company update and second quarter 2018 financial results 35

May 08, 2018: Infinity Pharmaceuticals Provides Company Update and First Quarter 2018 Financial Results 36

Nov 07, 2017: Infinity Provides Company Update and Reports Third Quarter 2017 Financial Results 38

Aug 03, 2017: Infinity Provides Company Update and Reports Second Quarter 2017 Financial Results 40

May 09, 2017: Infinity Provides Company Reports First Quarter 2017 Financial Results 43

Mar 14, 2017: Infinity Provides Company Update and Reports Fourth Quarter 2016 Financial Results 44

Corporate Communications 46

Aug 07, 2018: Infinity Pharmaceuticals appoints Samuel Agresta as Chief Medical Officer 46

Mar 08, 2018: Infinity Pharmaceuticals Announces Additions to Board of Directors and Clinical Leadership Team and Establishes Scientific Advisory Board 47

Feb 13, 2017: Infinity Announces Promotion of Jeffery Kutok, M.D., Ph.D. to Chief Scientific Officer 49

Jan 04, 2017: Infinity Announces Organizational Changes 50

Appendix 52

Methodology 52

About GlobalData 52

Contact Us 52

Disclaimer 52


List Of Figure

List of Figures

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Infinity Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 11

Bristol-Myers Squibb and Infinity Pharma Enter into Collaboration Agreement 12

Arcus Biosciences and Infinity Pharma Enter into Clinical Collaboration Agreement 13

Bristol-Myers Squibb Expands Agreement with Infinity Pharma 14

Pharm-Olam International Enters into Agreement with Infinity Pharma 15

Lead Discovery Center Partners with Infinity Pharma 16

PellePharm Enters into Licensing Agreement with Infinity Pharma 17

Verastem Enters into Licensing Agreement with Infinity Pharma for Duvelisib 18

FAAH Pharma Enters into Licensing Agreement with Infinity Pharma 20

Infinity Pharma Plans to Raise USD2.5 Million in Public Offering of Shares 21

Infinity Pharmaceuticals to Raise USD50 Million in Offering of Common Stock 23

Infinity Pharma Completes Public Offering Of Common Stock For USD 173 Million 24

Infinity Pharma Completes Private Placement Of Shares For USD 78.5 Million 26

Infinity Pharma Completes Public Offering Of Common Stock For USD 88 Million 27

Infinity Pharmaceuticals Inc, Key Competitors 29

Infinity Pharmaceuticals Inc, Key Employees 30

Infinity Pharmaceuticals Inc, Subsidiaries 31

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Infinity Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Infinity Pharmaceuticals Inc (Infinity Pharmaceuticals) is a biopharmaceutical company that discovers and develops small molecule therapeutics for the treatment of cancer. The company's pipeline candidate: IPI-549 selectively inhibits PI3K-gamma to reprogram tumor-associated macrophages and transforms immuno-oncology approach. It is evaluating IPI-549 as a monotherapy in Phase 2 for a solid tumor. Infinity Pharmaceuticals is also investigating IPI-549 in Phase 1 for solid tumors, and in Phase 1B for non-small cell lung cancer (NSCLC), melanoma, squamous cell carcinoma of the head and neck (SCCHN), triple negative breast cancer (TNBC), mesothelioma, adrenocortical carcinoma, and myeloid-derived suppressor cells (MDSC). Infinity Pharmaceuticals is headquartered in Cambridge, Massachusetts, the US.

Infinity Pharmaceuticals Inc (INFI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 11

Partnerships 12

Bristol-Myers Squibb and Infinity Pharma Enter into Collaboration Agreement 12

Arcus Biosciences and Infinity Pharma Enter into Clinical Collaboration Agreement 13

Bristol-Myers Squibb Expands Agreement with Infinity Pharma 14

Pharm-Olam International Enters into Agreement with Infinity Pharma 15

Lead Discovery Center Partners with Infinity Pharma 16

Licensing Agreements 17

PellePharm Enters into Licensing Agreement with Infinity Pharma 17

Verastem Enters into Licensing Agreement with Infinity Pharma for Duvelisib 18

FAAH Pharma Enters into Licensing Agreement with Infinity Pharma 20

Equity Offering 21

Infinity Pharma Plans to Raise USD2.5 Million in Public Offering of Shares 21

Infinity Pharmaceuticals to Raise USD50 Million in Offering of Common Stock 23

Infinity Pharma Completes Public Offering Of Common Stock For USD 173 Million 24

Infinity Pharma Completes Private Placement Of Shares For USD 78.5 Million 26

Infinity Pharma Completes Public Offering Of Common Stock For USD 88 Million 27

Infinity Pharmaceuticals Inc-Key Competitors 29

Infinity Pharmaceuticals Inc-Key Employees 30

Infinity Pharmaceuticals Inc-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Recent Developments 32

Strategy And Business Planning 32

Nov 07, 2018: Bristol-Myers and Infinity partner for trial of opdivo and IPI-549 32

Financial Announcements 33

Nov 05, 2018: Infinity Pharmaceuticals provides company update and third quarter 2018 financial results 33

Aug 07, 2018: Infinity Pharmaceuticals provides company update and second quarter 2018 financial results 35

May 08, 2018: Infinity Pharmaceuticals Provides Company Update and First Quarter 2018 Financial Results 36

Nov 07, 2017: Infinity Provides Company Update and Reports Third Quarter 2017 Financial Results 38

Aug 03, 2017: Infinity Provides Company Update and Reports Second Quarter 2017 Financial Results 40

May 09, 2017: Infinity Provides Company Reports First Quarter 2017 Financial Results 43

Mar 14, 2017: Infinity Provides Company Update and Reports Fourth Quarter 2016 Financial Results 44

Corporate Communications 46

Aug 07, 2018: Infinity Pharmaceuticals appoints Samuel Agresta as Chief Medical Officer 46

Mar 08, 2018: Infinity Pharmaceuticals Announces Additions to Board of Directors and Clinical Leadership Team and Establishes Scientific Advisory Board 47

Feb 13, 2017: Infinity Announces Promotion of Jeffery Kutok, M.D., Ph.D. to Chief Scientific Officer 49

Jan 04, 2017: Infinity Announces Organizational Changes 50

Appendix 52

Methodology 52

About GlobalData 52

Contact Us 52

Disclaimer 52


List Of Figure

List of Figures

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Infinity Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 11

Bristol-Myers Squibb and Infinity Pharma Enter into Collaboration Agreement 12

Arcus Biosciences and Infinity Pharma Enter into Clinical Collaboration Agreement 13

Bristol-Myers Squibb Expands Agreement with Infinity Pharma 14

Pharm-Olam International Enters into Agreement with Infinity Pharma 15

Lead Discovery Center Partners with Infinity Pharma 16

PellePharm Enters into Licensing Agreement with Infinity Pharma 17

Verastem Enters into Licensing Agreement with Infinity Pharma for Duvelisib 18

FAAH Pharma Enters into Licensing Agreement with Infinity Pharma 20

Infinity Pharma Plans to Raise USD2.5 Million in Public Offering of Shares 21

Infinity Pharmaceuticals to Raise USD50 Million in Offering of Common Stock 23

Infinity Pharma Completes Public Offering Of Common Stock For USD 173 Million 24

Infinity Pharma Completes Private Placement Of Shares For USD 78.5 Million 26

Infinity Pharma Completes Public Offering Of Common Stock For USD 88 Million 27

Infinity Pharmaceuticals Inc, Key Competitors 29

Infinity Pharmaceuticals Inc, Key Employees 30

Infinity Pharmaceuticals Inc, Subsidiaries 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Infinity Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.